Photo: chosun.com
Korean Firms Seize MASH Opportunity as Global Pharma Giants Exit Development
As global pharma giants exit MASH drug development, Korean firms like Hanmi and D&D Pharmatech seize the opportunity to advance treatments for obesity and diabetes, addressing rising health concerns.
- With a surge in obesity and diabetes cases, the need for effective treatments for Metabolic Dysfunction-Associated Steatohepatitis (MASH) is critical, yet only two therapies have received approval to date.
- AstraZeneca, Pfizer, and Novo Nordisk have suspended their drug development pipelines for MASH, unable to compete with existing treatments, leading to a vacuum in the market.
- Korean companies Hanmi and D&D Pharmatech are now advancing dual agonists in clinical trials, potentially addressing complications such as cirrhosis and fibrosis associated with metabolic disorders.
Por Qué Es Relevante
The exit of major pharmaceutical players from MASH development opens the door for innovative approaches by smaller firms, which may lead to breakthroughs in treating conditions highlighted by the American Association for the Study of Liver Diseases. This shift could significantly impact patient outcomes amid a growing health crisis.